David Amsellem
Stock Analyst at Piper Sandler
(2.57)
# 2,164
Out of 4,877 analysts
147
Total ratings
59.48%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Reiterates: Overweight | $328 | $279.21 | +17.47% | 4 | Jun 27, 2025 | |
| SAGE Sage Therapeutics | Downgrades: Neutral | $9 → $8.5 | $9.12 | -6.75% | 2 | Jun 17, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $115 | $125.59 | -8.43% | 1 | Jun 12, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $9.68 | +85.95% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $29.59 | +25.04% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $106.12 | +38.52% | 14 | May 7, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $160 → $154 | $125.69 | +22.52% | 10 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $65 | $46.29 | +40.42% | 1 | Apr 22, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $128 → $131 | $73.40 | +78.47% | 7 | Apr 3, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $36 → $32 | $22.95 | +39.43% | 8 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $4.69 | -14.62% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $14.74 | -11.80% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $8.93 | +11.98% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $16.76 | +79.00% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $8.86 | +46.81% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $8.09 | +35.97% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $28.61 | +29.33% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $65.25 | +4.21% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $31.52 | +14.23% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.66 | -54.95% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $23.88 | +75.88% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.31 | +202.11% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $0.71 | +2,851.51% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $104.37 | +8.27% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $31.60 | +32.91% | 3 | Oct 16, 2023 |
Amgen
Jun 27, 2025
Reiterates: Overweight
Price Target: $328
Current: $279.21
Upside: +17.47%
Sage Therapeutics
Jun 17, 2025
Downgrades: Neutral
Price Target: $9 → $8.5
Current: $9.12
Upside: -6.75%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $115
Current: $125.59
Upside: -8.43%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $9.68
Upside: +85.95%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $29.59
Upside: +25.04%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $106.12
Upside: +38.52%
Neurocrine Biosciences
May 6, 2025
Reiterates: Overweight
Price Target: $160 → $154
Current: $125.69
Upside: +22.52%
Bristol-Myers Squibb Company
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $46.29
Upside: +40.42%
Corcept Therapeutics
Apr 3, 2025
Maintains: Overweight
Price Target: $128 → $131
Current: $73.40
Upside: +78.47%
Amphastar Pharmaceuticals
Mar 21, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $22.95
Upside: +39.43%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $4.69
Upside: -14.62%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $14.74
Upside: -11.80%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $8.93
Upside: +11.98%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $16.76
Upside: +79.00%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $8.86
Upside: +46.81%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $8.09
Upside: +35.97%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $28.61
Upside: +29.33%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $65.25
Upside: +4.21%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $31.52
Upside: +14.23%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.66
Upside: -54.95%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $23.88
Upside: +75.88%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.31
Upside: +202.11%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $0.71
Upside: +2,851.51%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $104.37
Upside: +8.27%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $31.60
Upside: +32.91%